Notes

In September 2026, Meta, Manus, and OpenAI launched Muse, Cue, and dots, respectively, all designed to enable personal agents to handle ongoing daily and professional tasks. These products suggest a shift in the role of agents: moving from merely "helping me answer" to "taking over and executing the work." Muse is geared toward everyday life, such as shopping or travel, but incorporates independent security reviews, drawing a clear line between "handling a task on your behalf" and "authorizing the actual execution." Cue equips personal agents with access to phone, email, and computer systems, while dots functions more like an advanced office tool, also emphasizing continuous, long-term work. I am particularly drawn to its philosophy of "giving it a responsibility to own." In my experience using various coding agents, even with a well-prepared specification or plan, they often get stuck on minor details or grow increasingly "lazy" over time, requiring me to constantly nudge them and steer them back to the original roadmap. In contrast, dots is said to be capable of proactively determining the next logical steps and executing them, leaving only key decision-making to the user. I’m eager to test this by handing over some "vibe coding" projects to it. What I’m most curious to observe with these three products is whether, in the long run, people will truly entrust their to-do lists to them, and how frequently they will need to step back in to check on the progress.

I followed Anew Labs’ AnewDDE technical report. Anew Labs spun out of ByteDance’s internal drug discovery team, and ByteDance retained a majority stake after the financing. What caught my attention is how AnewDDE links protein structure, affinity evaluation, molecular design, and R&D reasoning in an experimental loop. In its VHH nanobody affinity-maturation round, 16 of 100 candidates measured in the single-digit nM range. I find that more interesting than a model leaderboard; next, I want to see whether similar hits recur across targets and translate into function. Beyond AnewDDE, the suite has gradually formed a comprehensive pipeline. Anew Labs does not merely provide an AI platform; rather, it aims to establish its own end-to-end drug discovery pipeline.